New drug combo aims to keep deadly blood cancer at bay
NCT ID NCT07244367
Summary
This study is testing whether a two-drug maintenance therapy can help keep acute myeloid leukemia (AML) from returning in fit patients who have achieved remission after strong chemotherapy. It is for patients aged 18-60 who are either waiting for a bone marrow transplant or cannot get one. The goal is to see if this treatment can extend the time patients remain cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Sohag university
RECRUITINGSohag, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sohag university hospital
RECRUITINGSohag, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.